ESR1 and breast carcinoma: Clinical phase 1 and 2 studies are currently ongoing with regard to monotherapy and combination therapy with CB-839 in solid tumors, including triple-negative breast cancer (NCT02071862, NCT03057600, NCT03875313) but not ERα-positive breast cancer [23].